Equities Analysts Set Expectations for Viridian Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:VRDN)

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for Viridian Therapeutics in a report released on Wednesday, August 14th. HC Wainwright analyst D. Tsao expects that the company will post earnings of ($0.98) per share for the quarter. HC Wainwright has a “Buy” rating and a $27.00 price objective on the stock. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($3.70) per share. HC Wainwright also issued estimates for Viridian Therapeutics’ Q2 2025 earnings at ($1.00) EPS.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.15). Viridian Therapeutics had a negative return on equity of 89.20% and a negative net margin of 79,185.77%. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.09 million.

Several other research analysts also recently weighed in on the company. Wedbush reiterated an “outperform” rating and set a $42.00 price target on shares of Viridian Therapeutics in a research note on Monday, July 29th. The Goldman Sachs Group initiated coverage on shares of Viridian Therapeutics in a report on Thursday, June 6th. They set a “buy” rating and a $23.00 price objective on the stock. Oppenheimer reaffirmed an “outperform” rating and set a $28.00 price objective (down from $31.00) on shares of Viridian Therapeutics in a report on Monday, August 12th. Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, June 11th. Finally, LADENBURG THALM/SH SH downgraded shares of Viridian Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, May 9th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $31.20.

Viridian Therapeutics Stock Performance

NASDAQ:VRDN opened at $15.49 on Thursday. The company has a market capitalization of $988.60 million, a P/E ratio of -3.44 and a beta of 1.13. The business has a fifty day simple moving average of $14.04 and a two-hundred day simple moving average of $15.44. The company has a debt-to-equity ratio of 0.05, a current ratio of 23.99 and a quick ratio of 23.99. Viridian Therapeutics has a 1 year low of $10.93 and a 1 year high of $24.18.

Institutional Investors Weigh In On Viridian Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. RTW Investments LP bought a new stake in shares of Viridian Therapeutics during the fourth quarter valued at about $13,195,000. Perceptive Advisors LLC increased its position in shares of Viridian Therapeutics by 71.1% during the fourth quarter. Perceptive Advisors LLC now owns 1,730,212 shares of the company’s stock valued at $37,684,000 after buying an additional 719,007 shares during the period. Vanguard Group Inc. increased its position in shares of Viridian Therapeutics by 7.8% during the first quarter. Vanguard Group Inc. now owns 3,234,279 shares of the company’s stock valued at $56,632,000 after buying an additional 233,331 shares during the period. Ameritas Investment Partners Inc. increased its position in shares of Viridian Therapeutics by 19.2% during the first quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock valued at $87,000 after buying an additional 799 shares during the period. Finally, Knights of Columbus Asset Advisors LLC increased its position in shares of Viridian Therapeutics by 420.9% during the fourth quarter. Knights of Columbus Asset Advisors LLC now owns 153,949 shares of the company’s stock valued at $3,353,000 after buying an additional 124,396 shares during the period.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.